2450results about How to "Reduce severity" patented technology

The invention relates to a concept for placing a subcutaneous device such as a sensor at a selected site within the body of a patient, e.g. to obtain blood glucose readings. In a first aspect, an insertion needle comprises an oblong needle body and a distal end portion, the distal end portion having a pointed distal tip allowing the needle to be introduced subcutaneously and a distally facing generally smooth surface, the body comprising along a portion thereof a longitudinal groove adapted to at least partially accommodate the subcutaneous device. In a second aspect, a combination of an insertion needle and a subcutaneous device form an oblong body portion and a distal end portion formed by either of the members or in combination by the two members, the distal end portion having a pointed distal tip and a distally facing generally smooth surface. By the above configuration, a concept is provided reducing the severity of the body response following transcutaneous placement of a device as well as reducing the pain associated with the insertion.

The present invention involves methods and systems for using electrical stimulation to treat neurological disorders. More particularly, the method comprises surgically implanting an electrical stimulation lead that is in communication with spinal nervous tissue associated with a first, second, or third cervical vertebral segment to result in spinal nervous tissue stimulation, thus treating a wide variety of neurological disorders.

The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking cessation, and normalization of blood lipid composition.

A method and apparatus are provided for protecting cardiac tissue from insult. The method comprises identifying the occurrence of an insult, such as a heart attack, and delivering electrical stimulation to one or more predetermined nerves in a patient's body in response to identifying the occurrence of the insult. The stimulation may be provided at the spinal canal or on the chest wall of the patient through cutaneous electrodes.

The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a biological agent, a metabolite thereof, a biological agently acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides methods of medical treatment that include administering the flowable composition into the ocular region of a mammal.

A bone resection tool for resecting an end of a bone along a surface having a curvature comprises a guide, a cutting tool and a track follower. The guide is configured to be removably attached in a fixed position to the end of the bone. The guide is configured to include a track exhibiting a curvature generally corresponding to the curvature of the surface to be resected in the bone. The cutting tool includes a cutting face. The track follower is configured to couple to the cutting tool and cooperate with the track to facilitate reciprocation of the cutting tool relative to the guide to induce the cutting face to resect the bone along the surface having the curvature. A method for cutting a bone along a curved surface conforming to the curvature of a curved surface of the underside of a prosthetic component comprises the steps of incising the tissue surrounding the surface of the bone, positioning a guide alongside the surface of a bone to be cut, affixing the guide to the bone, interconnecting a cutter having a cutting face with the guide, maintaining the cutting face generally parallel to the tangent of the curved surface and traversing the cutting face along the bone while guiding the cutter along the track. The tissue incision incises the tissue surrounding the surface of the bone to be cut in a minimally invasive fashion. The positioned guide includes a track configured to assimilate the curvature of the curved surface of the underside of the prosthetic component.

The present invention relates to bioabsorbable polymeric coatings with antimicrobial agents that provide coated surfaces that resist protein absorption and infectious formation on coated surfaces of medical devices that are inserted or implanted in patients, and kits thereof with an antimicrobial disc.

This invention relates to a method of reducing an irritating or adverse side effect associated with the topical use of an active ophthalmic drug comprising incorporating an effective amount of a cyclodextrin or cyclodextrin derivative into a formulation to complex the active drug such that the concentration of the free active drug is reduced below a tolerable threshold, and incorporating an effective amount of a viscosity increasing agent in said formulation such that the bioavailability of said drug is high enough to be therapeutically effective, wherein the cyclodextrin or cyclodextrin derivative is not required to solubilize the active drug. Another aspect of this invention relates to topical ophthalmic formulations comprising an active drug, a cyclodextrin or cyclodextrin derivative, and a viscosity-enhancing agent, in effective amounts as stated above.

The present invention involves placing a valve between the left atrium and the lung to prevent regurgitant flow from increasing the pulmonary pressures, which may lead to pulmonary edema and congestion. Mitral stenosis or poor synchronization of the mitral valve may add additional pressures to the left atrium thus raising the pulmonary pressures and leading to congestion in the lung vasculature. By blocking the additional pressures from the mitral regurgitant flow from reaching the pulmonary circulation, the left atrium may act as a sealed vessel to allow additional aortic output. The valve placement can be intralumenal or attached to the ostium of the atrium. The device can be placed via the vascular conduits or through a surgical procedure into the pulmonary circulation. One or more devices may be placed in each of the four pulmonary veins. Additionally only one, two, three or all four veins may be implanted with the valve as desired by the physician.

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

This invention relates to improved vertebroplasty procedures for reducing embolisms, leakage and cement loosening.

Methods and compositions for treating, preventing, or diagnosing epidermal or dermal disorders, e.g., psoriasis, are disclosed. The methods and compositions of the invention use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).

The present invention relates to compounds of formula I:or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

A method and apparatus for reducing the longitudinal aspect of the catheter to stent force comprises at least one grip member for use with a stent delivery system. The grip engages a stent in the unexpanded state prior to delivery of the stent by retracting a stent retaining sheath. The grip comprises a body region having an outer diameter, a first end and a second end. The outer diameter of the first end is greater than the outer diameter of the second end. The grip is at least partially constructed from a polymeric material.

A method for operating a motor vehicle (1), particularly the supply of power to a motor vehicle (1), during and / or in the time period following a collision, wherein the motor vehicle (1) is at least partially deenergized, wherein the supply of electrical power of a vehicle system (9) is determined and switched during and / or following the collision based on at least one criterion (15).

The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and / or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and / or other conditions that cause such lesions. The invention also relates to kits for treatment and / or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Morpholino oligomers containing both uncharged and cationic intersubunit linkages are provided. The oligomers are oligonucleotide analogs containing predetermined sequences of base-pairing moieties. The presence of the cationic intersubunit linkages in the oligomers, typically at a level of about 10-50% of total linkages, provides enhanced antisense activity, in various antisense applications, relative to the corresponding uncharged oligomers. Also provided are such oligomers conjugated to peptide transporter moieties, where the transporters are preferably composed of arginine subunits, or arginine dimers, alternating with neutral amino acid subunits.

The invention relates to the improvement in the treatment of certain neural disorders / diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration.

The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.

The present invention is directed to controlled-release composition containing a solubilized material comprising an active agent and at least one oil-based surfactant capable of solubilizing the active agent, the solubilized material dispersed in a controlled-release particulate matrix.

Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.

A method and apparatus are provided for protecting cardiac tissue from insult. The method comprises identifying the occurrence of an insult, such as a heart attack, and delivering electrical stimulation to one or more predetermined nerves in a patient's body in response to identifying the occurrence of the insult. The stimulation may be provided to peripheral nerves, intrinsic cardiac nerves, sympathetic ganglia, cranial nerves, and may generally be directed to the vertebral column, or within the chest wall of the patient.

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and / or ameliorating diseases and disorders associated with aberrant expression and / or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

A system and method are disclosed for preventing accidents in a vehicle. The system comprises an eye gaze detector for receiving an eye gaze vector from a driver. The system additionally comprises a proximity sensor for detecting locations of nearby objects and their velocities. A vehicle accident risk is determined based on the nearby object location and velocity. Additionally, the driver's knowledge of vehicle circumstances is determined based on the nearby object location and velocity as well as the eye gaze location. Responsive to the driver's knowledge and the vehicle accident risk, a vehicle alert is activated.

Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.